+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Viral Vector and Plasmid DNA: Technologies and Global Markets- Product Image
Viral Vector and Plasmid DNA: Technologies and Global Markets- Product Image
New

Viral Vector and Plasmid DNA: Technologies and Global Markets

  • PDF Icon

    Report

  • 128 Pages
  • March 2024
  • Region: Global
  • BCC Research
  • ID: 4843088
Description Jump to:

The global market for viral vector and plasmid DNA technologies is expected to grow from USD 2.9 Billion in 2023 to USD 7.1 Billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.70% from 2023 through 2028.

Report Scope

The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market focusing cell and gene therapies, along with detailed competitive landscape and profiles of key market players that include revenue, product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges, and opportunities. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors, and exporters should find the information about market development and trends useful. The study segments the market on the basis of product type, applications, and end use. Geographical market analysis is provided for all the major segments. The report offers country-level analysis of markets to provide a better understanding of the major segments.

The market is divided into segments and by application/industry as follows

By product type

  • Viral vector
  • Plasmid DNA

By application

  • Cancer
  • Genetic disorders
  • Infectious diseases
  • Cardiovascular diseases.
  • Other diseases

By end-user

  • Research institutes
  • Pharmaceutical and biopharmaceutical companies

Each area is covered in detail, identifying current products in the market in the base year (2022), measuring the current market size and identifying current and potential market drivers, forecasting for 2028, assessing current and potential competitors, and identifying current competitor market shares for 2022.

Report Includes

  • 93 data tables and 47 additional tables
  • An overview of the global market for viral vector and plasmid DNA
  • Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Evaluation of the current market size and revenue growth prospects for viral vector and plasmid DNA, along with a market share analysis by product type, application and geographic region
  • A look at the innovations, technological advances, and product launches from leading companies
  • Analysis of the industry’s regulatory framework and policies, and its product pipeline
  • Discussion of ESG challenges and ESG practices
  • Analysis of the key companies’ market shares, proprietary technologies, strategic alliances and other market strategies, and patents
  • Profiles of the leading players in the industry

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
Chapter 2 Market Overview
  • Viral Technology
  • Cell and Gene Therapy
Chapter 3 Market Dynamics
  • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
Chapter 4 Emerging Technologies and Developments
  • Overview
  • AI in Viral Vector Production
  • Doggy Bone DNA
  • FRAGment Recycler: A New Technology for Plasmid DNA Synthesis
  • Patents
  • Patent Holdings by Manufacturer
  • Clinical Trials
  • Selected Clinical Trials of Viral Vectors and Plasmid DNA Technologies
Chapter 5 Global Market for Viral Vector and Plasmid DNA Technologies
  • Segmentation Breakdown
  • Market Breakdown by Product Type
  • Market Breakdown by End User
  • Research Institutes
  • Pharmaceutical and Biopharmaceutical Companies
  • Market Breakdown by Application
  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Cardiovascular Diseases
  • Other Diseases
  • Geographic Breakdown
  • Market Breakdown by Region
  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 6 Competitive Intelligence
  • Industry Scenario
  • Company Shares
  • Competitive Landscape among Companies
  • Competitive Landscape in Viral Vectors
  • Competitive Landscape in Plasmid DNA
Chapter 7 Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective
  • Introduction
  • Environmental Factors
  • Social Factors
  • Governance Factors
  • ESG Performance among Major Companies
  • ESG Performance of Select Companies
  • Lonza: ESG Performance
  • Thermo Fisher Scientific: ESG Performance
  • Conclusion
Chapter 8 Appendix
  • Research Methodology
  • Acronyms
  • References
  • Company Profiles
  • Agilent Technologies Inc.
  • Bluebird Bio Inc.
  • Catalent Inc.
  • Danaher Corp.
  • Fujifilm Holdings Corp.
  • Genscript
  • Gilead Sciences Inc.
  • Lonza
  • Novartis Ag
  • Oxford Biomedica Plc
  • Plasmidfactory Gmbh
  • Regenxbio Inc.
  • Thermo Fisher Scientific Inc.
  • VGXI Inc.
List of Tables
Summary Table: Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 1: Global Incidence of All Cancers, by WHO Region, 2022-2050
Table 2: Global Incidence of Leukemia, by WHO Region, 2022-2050
Table 3: Global Incidence of Hodgkin Lymphoma, by WHO Region, 2022-2050
Table 4: Global Incidence of Non-Hodgkin Lymphoma, by WHO Region, 2022-2050
Table 5: Global Incidence of Multiple Myeloma, by WHO Region, 2022-2050
Table 6: Patents Held by Oxford Biomedica, 2021-Present
Table 7: Selected Patents Held by Lonza, 2021-Present
Table 8: Patents Held by Regenxbio, 2021-Present
Table 9: Selected Clinical Trials, by Viral Vector Type
Table 10: Global Market for Viral Vector and Plasmid DNA Technologies, Through 2028
Table 11: Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 12: Global Market for Plasmid DNA Technology, by Region, Through 2028
Table 13: Global Market for Viral Vector Technology, by Region, Through 2028
Table 14: Global Market for Viral Vector and Plasmid DNA Technologies, by End User, Through 2028
Table 15: Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, Through 2028
Table 16: Global Market for Viral Vector and Plasmid DNA Technologies in Research Institutes, by Region, Through 2028
Table 17: Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, Through 2028
Table 18: Global Market for Viral Vector and Plasmid DNA Technologies in Pharmaceutical and Biopharmaceutical Companies, by Region, Through 2028
Table 19: Global Market for Viral Vector and Plasmid DNA Technologies, by Application, Through 2028
Table 20: Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 21: Global Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Region, Through 2028
Table 22: North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 23: North American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 24: Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 25: Latin American Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 26: European Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 27: European Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 28: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 29: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cancer, by Country, Through 2028
Table 30: RoW Market for Viral Vector and Plasmid DNA Technologies in Cancer, Through 2028
Table 31: Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 32: Global Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Region, Through 2028
Table 33: North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 34: North American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 35: Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 36: Latin American Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 37: European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 38: European Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 39: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 40: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, by Country, Through 2028
Table 41: RoW Market for Viral Vector and Plasmid DNA Technologies in Genetic Disorders, Through 2028
Table 42: Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 43: Global Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Region, Through 2028
Table 44: North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 45: North American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 46: Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 47: Latin American Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 48: European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 49: European Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 50: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 51: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, by Country, Through 2028
Table 52: RoW Market for Viral Vector and Plasmid DNA Technologies in Infectious Diseases, Through 2028
Table 53: Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 54: Global Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Region, Through 2028
Table 55: North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 56: North American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 57: Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 58: Latin American Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 59: European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 60: European Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 61: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 62: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, by Country, Through 2028
Table 63: RoW Market for Viral Vector and Plasmid DNA Technologies in Cardiovascular Diseases, Through 2028
Table 64: Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 65: Global Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Region, Through 2028
Table 66: North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 67: North American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
Table 68: Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 69: Latin American Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
Table 70: European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 71: European Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country, Through 2028
Table 72: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 73: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, by Country/Region, Through 2028
Table 74: RoW Market for Viral Vector and Plasmid DNA Technologies in Other Diseases, Through 2028
Table 75: Global Market for Viral Vector and Plasmid DNA Technologies, by Region, Through 2028
Table 76: North American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 77: North American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 78: Latin American Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 79: Latin American Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 80: European Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 81: European Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 82: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 83: Asia-Pacific Market for Viral Vector and Plasmid DNA Technologies, by Country, Through 2028
Table 84: RoW Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
Table 85: ESG Rankings of Major Companies, 2024*
Table 86: Lonza: ESG Performance
Table 87: Thermo Fisher Scientific Inc.: ESG Performance
Table 88: Acronyms Used in This Report
Table 89: Agilent Technologies Inc.: Company Snapshot
Table 90: Agilent Technologies Inc.: Financial Performance, FY 2021 and 2022
Table 91: Agilent Technologies Inc.: Product Portfolio
Table 92: Agilent Technologies Inc.: News/Key Developments, 2023
Table 93: Bluebird Bio Inc.: Company Snapshot
Table 94: Bluebird Bio Inc.: Financial Performance, FY 2021 and 2022
Table 95: Bluebird Bio Inc.: Product Portfolio
Table 96: Bluebird Bio Inc.: Key News/Developments, 2022
Table 97: Catalent Inc.: Company Snapshot
Table 98: Catalent Inc.: Financial Performance, FY 2021 and 2022
Table 99: Catalent Inc.: Product Portfolio
Table 100: Catalent Inc.: Key News/Developments, 2021-2024
Table 101: Danaher Corp.: Company Snapshot
Table 102: Danaher Corp.: Financial Performance, FY 2021 and 2022
Table 103: Danaher Corp.: Product Portfolio
Table 104: Danaher Corp.: News/Key Developments, 2022
Table 105: Fujifilm Holdings Corp.: Company Snapshot
Table 106: Fujifilm Holdings Corp.: Financial Performance, FY 2021 and 2022
Table 107: Fujifilm Holdings Corp.: Product Portfolio
Table 108: Fujifilm Holdings Corp.: News/Key Developments, 2022
Table 109: GenScript: Company Snapshot
Table 110: GenScript: Financial Performance, FY 2021 and 2022
Table 111: GenScript: Product Portfolio
Table 112: GenScript: News/Key Developments, 2023
Table 113: Gilead Sciences Inc.: Company Snapshot
Table 114: Gilead Sciences Inc.: Financial Performance, FY 2021 and 2022
Table 115: Gilead Sciences Inc.: Product Portfolio
Table 116: Gilead Sciences Inc.: News/Key Developments, FY 2021-2022
Table 117: Lonza: Company Snapshot
Table 118: Lonza: Financial Performance, FY 2021 and 2022
Table 119: Lonza: Product Portfolio
Table 120: Lonza: News/Key Developments, FY 2022
Table 121: Novartis AG: Company Snapshot
Table 122: Novartis AG: Financial Performance, FY 2021 and 2022
Table 123: Novartis AG: Product Portfolio
Table 124: Novartis AG: News/Key Developments, FY 2022
Table 125: Oxford Biomedica Plc: Company Snapshot
Table 126: Oxford Biomedica Plc: Financial Performance, FY 2021 and 2022
Table 127: Oxford Biomedica Plc: Product Portfolio
Table 128: Oxford Biomedica Plc: News/Key Developments, FY 2022
Table 129: PlasmidFactory GmbH: Company Snapshot
Table 130: PlasmidFactory GmbH: Product Portfolio
Table 131: Regenxbio Inc.: Company Snapshot
Table 132: Regenxbio Inc: Financial Performance, FY 2021 and 2022
Table 133: Regenxbio Inc: Product Portfolio
Table 134: Regenxbio Inc.: News/Key Developments, FY 2022
Table 135: Thermo Fisher Scientific Inc.: Company Snapshot
Table 136: Thermo Fisher Scientific Inc.: Financial Performance, FY 2021 and 2022
Table 137: Thermo Fisher Scientific Inc.: Product Portfolio
Table 138: VGXI Inc.: Company Snapshot
Table 139: VGXI Inc.: Product Portfolio
List of Figures
Summary Figure A: Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, 2020-2028
Summary Figure B: Global Market Shares of Viral Vector and Plasmid DNA Technologies, by Product Type, 2022
Figure 1: Viral Vector and Plasmid DNA Technologies: Market Dynamics
Figure 2: Approved Cell and Gene Therapy Product Count, 2003 to the Present
Figure 3: Emerging Trends/Technologies in Viral Vector and Plasmid DNA Technologies
Figure 4: Global Company Market Shares of Viral Vector and Plasmid DNA Technologies, 2022
Figure 5: Global Company Market Shares of Viral Vectors, 2022
Figure 6: Global Company Market Shares of Plasmid DNA, 2022
Figure 7: Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2022
Figure 8: Agilent Technologies Inc.: Revenue Share, by Region, FY 2022
Figure 9: Catalent Inc.: Revenue Share, by Business Unit, FY 2022
Figure 10: Catalent Inc.: Revenue Share, by Country/Region, FY 2022
Figure 11: Danaher Corp.: Revenue Share, by Business Unit, FY 2022
Figure 12: Danaher Corp.: Revenue Share, by Country/Region, FY 2022
Figure 13: Fujifilm Holdings Corp.: Revenue Share, by Business Unit, FY 2022
Figure 14: Fujifilm Holdings Corp.: Revenue Share, by Country/Region, FY 2022
Figure 15: GenScript: Revenue Share, by Business Unit, FY 2022
Figure 16: GenScript: Revenue Share, by Country/Region, FY 2022
Figure 17: Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2022
Figure 18: Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2022
Figure 19: Lonza: Revenue Share, by Business Unit, FY 2022
Figure 20: Lonza: Revenue Share, by Country/Region, FY 2022
Figure 21: Novartis AG: Revenue Share, by Business Unit, FY 2022
Figure 22: Novartis AG: Revenue Share, by Country/Region, FY 2022
Figure 23: Oxford Biomedica Plc: Revenue Share, by Business Unit, FY 2022
Figure 24: Oxford Biomedica Plc: Revenue Share, by Country/Region, FY 2022
Figure 25: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2022
Figure 26: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2022

Samples

Loading
LOADING...

Executive Summary

Viral vectors are viruses developed through cultured DNA recombination techniques. This modification makes the viruses ideal for delivering genetic material into target cells or tissues for therapeutic purposes. Types of viral vectors include adenoviruses, retroviruses, poxviruses, adeno-associated viruses (AAV), and herpes simplex viruses (HSVs). Delivery of foreign DNA using viral vectors has flaws, particularly when attempts are made to apply the technology to gene therapy. However, as researchers learn more about viral vectors and their impact on human immune response, advancements in safe and effective viral-based treatments continue. Meanwhile, the refinement of viral-mediated gene delivery protocols proceeds, providing a convenient, flexible, and reproducible system for in vitro transfection studies. Plasmid DNA vaccines offer speed, simplicity, and breadth of immune response by overcoming the issues regarding effectiveness and safety of therapy during treatment. Innovative plasmid DNA vaccines can be useful for the immunization of humans against infectious diseases and cancers.

The global viral vector and plasmid DNA technologies market’s projected growth stems from factors such as the rising prevalence of various diseases such as cancer, infectious diseases, and other genetic disorders, the growing trend toward gene therapy owing to their promising clinical results, and increasing partnerships and collaborations between companies and research institutes in gene therapy.

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market. According to the WHO (World Health Organization), cancer is the second-leading cause of mortality in the world, responsible for 9.6 million deaths and accounting for 18.1 million new cases in 2018. Consequently, there is significant demand for cancer therapeutics based on innovative technologies such as viral vectors and plasmid DNA. Viral vectors are being researched for applications in cancer therapies and to support the delivery of genetic information to a tumor, which will permit the development of therapeutic proteins. The process typically involves introducing DNA into a cell (transfection), which encodes for a protein and other important genetic elements needed for the introduction of the gene of interest expression that facilitates successful production of protein. Some approved gene therapies, like Kymriah for acute lymphoblastic leukemia (ALL) and large B cell lymphoma, have induced market players to research and develop gene therapy for cancer treatment. However, regulatory challenges, vector characterization, and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.

The global viral vector and plasmid DNA technologies market was segmented based on the product, application, and end-user. Based on the product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors. The viral vector is the most operative resource of gene transfer to modify specific cell type or tissue and can be manipulated to express therapeutic genes. Various types of viruses include adenoviruses, retroviruses (?-retroviruses and lentiviruses), poxviruses, AAV, baculoviruses, and HSV. These viruses are under investigation as applications to deliver genes to cells for either transient or permanent transgene expression. The rising applications of these viruses should boost the growth of the viral vector in gene therapy.


Companies Mentioned

  • Agilent Technologies Inc.
  • Bluebird Bio Inc.
  • Catalent Inc.
  • Danaher Corp.
  • Fujifilm Holdings Corp.
  • Genscript
  • Gilead Sciences Inc.
  • Lonza
  • Novartis Ag
  • Oxford Biomedica Plc
  • Plasmidfactory Gmbh
  • Regenxbio Inc.
  • Thermo Fisher Scientific Inc.
  • VGXI Inc

Table Information

Report AttributeDetails
No. of Pages128
PublishedMarch 2024
Forecast Period2023 - 2028
Estimated Market Value ( USD ) in 2023 $ 2.9 Billion
Forecasted Market Value ( USD ) by 2028 $ 7.1 Billion
Compound Annual Growth Rate19.7%
Regions CoveredGlobal
No. of Companies Mentioned14

Related Topics

Related Reports

Viral Vector and Plasmid DNA Manufacturing Market - Global Forecast to 2028 - Product Image

Viral Vector and Plasmid DNA Manufacturing Market - Global Forecast to 2028

  • Report
  • 317 Pages
  • Global
From
Viral Vectors and Plasmid DNA Global Market Report 2024 - Product Image

Viral Vectors and Plasmid DNA Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Viral Vectors and Plasmid DNA Manufacturing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts- 2023 to 2031 - Product Image

Viral Vectors and Plasmid DNA Manufacturing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts- 2023 to 2031

  • Report
  • 113 Pages
  • Global
From
Global Viral Vector & Plasmid DNA Manufacturing Market by Type (Plasmid DNA, Viral Vector), Cell Line (In-vitro, In-Vivo), Transfection, Indication, Workflow, Application, End User - Forecast 2023-2030 - Product Image

Global Viral Vector & Plasmid DNA Manufacturing Market by Type (Plasmid DNA, Viral Vector), Cell Line (In-vitro, In-Vivo), Transfection, Indication, Workflow, Application, End User - Forecast 2023-2030

  • Report
  • 193 Pages
  • Global
From
Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Size, Share, Trends Opportunity, and Forecast 2018-2028 - Product Image

Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Size, Share, Trends Opportunity, and Forecast 2018-2028

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.